Advisory Board May 22, 2024
Weight-loss drugs like Wegovy and Zepbound are in high demand, but their expensive price tags have made them unaffordable for many patients. However, some telehealth companies are now offering their own versions of these weight-loss drugs at a significant discount — something that could significantly increase access to these medications.
Resource library: Weight management and obesity care
High costs of GLP-1 drugs push out low-income patients
GLP-1 agonists, which include Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, were originally approved to treat diabetes. Over the last few years, FDA has also approved rebranded versions of these drugs, including Novo’s Wegovy and Lilly’s Zepbound, to treat obesity.
Although these drugs are in high demand, their high costs have made it difficult...
Today's Sponsors
Today's Sponsor